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Abstract
Objectives—There is a lack of unanimity
about (increased) serum levels of creatine
kinase (CK) in patients with ankylosing
spondylitis (AS), perhaps because of the
inclusion of inappropriate controls.
Therefore, serum levels of biochemical
markers of muscle origin were assessed in
AS patients compared with controls.
Methods—In a comparative study serum
levels of sarcoplasmic proteins indicating
muscle cell leakage, creatinine, and C
reactive protein (CRP) were measured.
Fifty eight AS patients with a mean
disease duration of 22 (SD 11) years and 58
age and sex matched controls (without
back complaints) were included.
Results—Lower serum levels in AS pa-
tients compared with controls were found
for CK (mean (SD): 46 (21) v 76 (44) IU/l;
p<0.001), aldolase (0.43 (0.36) v 0.58 (0.32)
IU/l; p=0.001), creatinine (91 (13) v 96 (11)
µmol/l; p=0.02), alanine aminotransferase
(2.8 (1.5) v 4.1 (2.9) IU/l; p=0.001) and
aspartate aminotransferase (7.0 (2.7) v 8.4
(3.5) IU/l; p=0.02). Also the lean body
mass, as estimated by a formula using
height, weight, age and sex, showed lower
values in patients versus controls (56 (9) v
59 (9) kg; p=0.004), but creatinine clear-
ance (by Cockcroft and Gault formula)
was not diVerent (p=0.48). Partial corre-
lation coeYcients adjusted for age and sex
showed that CRP levels correlated nega-
tively with CK and aldolase levels in AS
patients (r= −0.48, p<0.001 and r= −0.37,
p=0.005, respectively).
Conclusion—Serum levels of biochemical
markers of muscle origin were lower in
AS patients compared with controls.
Patients with active AS, as reflected by
high CRP levels, may have an increased
protein degradation, predominantly in
skeletal muscle.
(Ann Rheum Dis 1999;58:541–545)
Ankylosing spondylitis (AS) is a chronic
inflammatory disease that primarily aVects the
sacroiliac joints and the spine. Frequently, it is
accompanied by asymmetric arthritis of
peripheral joints, uveitis anterior, and other
extraspinal manifestations. There is uncer-
tainty whether skeletal muscle is directly
involved in the inflammatory process of AS,
because muscle changes may also be a
consequence of disuse attributable to the pain
associated with joint inflammation. Proteins of
muscle origin are continually degraded and
replaced every one or two weeks.1 Among those
muscle proteins are the intracellular sarcoplas-
mic enzymes, such as creatine kinase (CK),
aldolase, alanine aminotransferase (ALT) and
aspartate aminotransferase (AST), which may
circulate in peripheral blood because of muscle
membrane vulnerability and leakage. Serum
levels of these enzymes may be indicative of
muscle mass. CK, which catalyses the revers-
ible phosphorylation of creatine by ATP as a
quickly withdrawable energy reserve, is found
in many tissues, but is mainly concentrated in
skeletal muscle, brain and heart. Aldolase is
responsible for the conversion of fructose-1,6-
biphosphate into glyceraldehyde-3-phosphate
and dihydroxyacetone phosphate in the glyco-
lytic pathway.2 Aldolase is rather specific for
skeletal muscle, but is also found in liver, heart,
brain, and other tissues. AST and ALT are well
known markers of liver disease, but these
enzymes, together with creatinine, are also
derived from skeletal muscle.3
Conflicting data have been published as to
serum levels of biochemical markers of muscle
origin in patients with AS. In a study by Calin4
increased CK levels were found in 43 patients
with AS compared with 82 controls, among
whom were an unspecified number of patients
with polymyalgia rheumatica and rheumatoid
arthritis. These latter diseases are known to be
associated with reduced CK levels,5 6 and may,
therefore, be less appropriate control condi-
tions. Increased AS disease activity, measured
through finger to floor distance, was negatively
associated with CK levels.4 Moreover, 30
patients with AS again showed increased CK
levels compared with 22 controls, who were
patients with spondylosis and lumbar disc
degeneration.7 In uncontrolled studies, 5 of 31
(16%),8 2 of 19 (11%),9 or none of 1010 patients
with AS showed increased CK levels against
normal reference values. A small11 and a large
study5 did not show a significant diVerence in
CK levels between patients with AS and
controls. In the larger study, the 103 controls
were all patients with non-inflammatory
arthropathies, yet included patients with low
back pain.5 Taken together, these studies have
demonstrated contradictory data of muscle
enzyme levels in patients with AS. The aim of
our study was to compare serum levels of CK
and other biochemical markers, known to be
related to skeletal muscle, in AS patients versus
carefully selected, age and sex matched con-
trols, without inflammatory rheumatic disease
or low back pain.
Methods
Male or female patients > 18 years old, fulfilling
theNewYork 1984 criteria for definite AS,12 and
with radiological involvement of the spine
defined by > 1 syndesmophyte on a radiograph
were included. For every AS patient a control
subject was selected, of the same sex, and not
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more than two years older or younger. Controls
were either members of the healthy clinic staV,
or were outpatients with soft tissue rheumatism,
but without complaints of the back. The
subjects were originally recruited to study sex
steroid hormonal levels.13 The current mean age
of AS patients was 48 years (range 28 to 70) and
of controls 48 (28 to 72). The body mass index
(BMI=weight/height2) was calculated in all sub-
jects. None of the subjects had concomitant
endocrine, cardiac disease, neoplastic or im-
mune disease, or used sex steroid hormones,
anti-androgenic medication, or corticosteroids
during the past four weeks. Two male patients
with AS (as well as their two matched controls)
were excluded from the present analyses, one
because of known kidney failure and one
because of an intramuscular injection with
corticosteroids two weeks before the blood sam-
pling. Informed consent was obtained from all
subjects, and the study was approved by the
ethical review board.
Non-fasting blood samples were obtained
before noon, to assess CK (using a kinetic
method, normal range for men <130 IU/l and
for women <110 IU/l), aldolase (using a kinetic
method, normal range < 7.6 IU/l), creatinine
(using the calorimetric JaVé method, normal
range < 124 µmol/l),14 AST (using a kinetic
method, normal range < 25 IU/l) and ALT
(using a kinetic method, normal range for < 35
IU/l). As serum enzyme levels might be
decreased as a consequence of an increased
glomerular filtration rate,15 we estimated the
creatinine clearance rates using the Cockcroft
and Gault formula.16 The current use of medi-
cation was recorded, and total energy of food
intake was estimated by a validated Dutch
semiquantitative food frequency question-
naire.17
As CK levels may be a marker of muscle
mass, we estimated the lean body mass (LBM)
by sex specific formula using weight and
height. In a separate group of healthy subjects
(44 men and 30 women) with a mean age of 27
year (range 16–43), we validated the LBM
estimation by formula of Hume,18 which have
previously been used in a study on CK levels in
rheumatoid arthritis,6 and of Deurenberg et al19
by comparing its values to LBM assessed by
bioelectrical impedance analysis (BIA 101/S,
RJL Systems, Detroit, MI).20 We used baseline
data from subjects who were included in stud-
ies on the eVects of sex hormone administra-
tion.21 The BIA method, which has been
validated by the underwater weighing reference
method,22 is based on the conductivity of an
electric current by the electrolytes present in
the lean tissues. Subjects were placed in a
supine position with the limbs abducted from
the body. Four electrodes were placed to meas-
ure whole body resistance and reactance of the
electric current. LBM was calculated with use
of the manufacturer’s equations. Spearman’s
correlation coeYcients for the LBM estimated
by BIA was 0.95 (p<0.001) when correlated
with the prediction from the formula of Hume,
and was 0.97 (p<0.001) when correlated with
the prediction from the formula of Deurenberg
et al (fig 1). A strong correlation was, however,
guaranteed because of the wide range of LBM
and because weight and height are part of the
Figure 1 Scatter plot showing the association between
LBM using the formula of Deurenberg et al19 and the LBM
estimated by BIA20 in 44 healthy men and 30 healthy
women. Spearman’s correlation coeYcient is given, as well
as a dotted line of equality on which all points would lie if
the two estimates gave the same results.
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Figure 2 Serum levels of creatine kinase (on a logarithmic scale), aldolase, creatinine,
aspartate aminotransferase and alanine aminotransferase, and the estimated lean body
mass by a formula of Deurenberg et al,19 in 58 patients with ankylosing spondylitis
compared with 58 age and sex matched controls. The p values were assessed by t tests for
paired samples.
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formulas by all techniques. The mean difference
(95% confidence intervals) for the estimate and
BIA was −2.4 kg (−3.3 to −1.4) for the formula
of Hume, and was −0.3 kg (−0.8 to 0.3) for the
formula of Deurenberg et al. The 95% limits of
agreement as described by Bland and Altman,23
were −10.0 to 5.3 kg for the formula of Hume
and −4.8 to 5.0 kg for the formula of
Deurenberg et al. Thus, the formula of Hume
may systematically underestimate the LBM,
which was especially evident in men. Further-
more, the lack of agreement of the formula of
Hume with BIAmay be because of the inclusion
of patients with several disorders and the
absence of a “gold standard” technique measur-
ing LBM.18 To estimate LBM in our patients
with AS we used the formula of Deurenberg et
al19 (with LBM in kg, body height in m, body
weight in kg, age in years, and sex = 1 for men
and sex = 0 for women):
LBM = (1 − ((1.20 × (weight/height2) + 0.23
× age −10.8 × sex −5.4)/100)) × weight
STATISTICAL ANALYSIS
Variables with distributions that were skewed
to the right (aldolase, CK and CRP) were loga-
rithmically transformed before analysis to
approximately normalise their distributions. A
paired samples t test was used for inter-group
comparisons. A t test for independent samples
or an analysis of covariance (ANCOVA), to
adjust for age, were used to compare variables
in diVerent groups of patients. Values were
correlated using partial correlation coeYcients
to adjust for age and sex, or other potential
confounding variables. If aldolase or CRP lev-
els were below the lower limit of detection (0.1
IU/l and 1 mg/l, respectively) those values were
used. A two sided p<0.05 was considered
statistically significant. The software used was
SPSS for Windows 7.0 (Chicago, IL).
Results
Forty eight male and 10 female AS patients
(all white) and 48 male and 10 female controls
(56 white) were included in the study. One
female control had an Indonesian father and
Dutch mother, while another female control
was of Indonesian origin herself. The mean
(SD) disease duration was 22 (11) years. The
current daily medication of AS patients
consisted of non-steroidal anti-inflammatory
drugs (NSAID, n=39) or second line antirheu-
matics (n=17). Fourteen AS patients used no
medication at all. Controls were either healthy
(n=30), or had complaints of osteoarthritis
(n=9), painful shoulders (n=8), aspecific
myalgia (n=4), or other non-inflammatory
peripheral musculoskeletal complaints (n=7).
Patients did not diVer from controls with
respect to age (mean (SD): 48 (10) v 48 (10)
year), BMI (25.6 (3.4) v 26.0 (3.2) kg/m2;
p=0.53), and the estimated glomerular filtra-
tion rate (97 (20) v 99 (24) ml/min; p=0.48).
Neither the glomerular filtration rate nor any
biochemical marker of muscle origin did
significantly diVer in 44 patients using
NSAIDs compared with 14 not using NSAIDs
(p>0.33 for all), but CRP levels were slightly
higher in the patients using NSAIDs com-
pared with those not using NSAIDs (geomet-
ric mean: 12.6 v 6.5 mg/l, p=0.06). The
number of alcohol consumptions and the total
energy of food intake per day did not diVer
between AS patients and controls (p=0.34 and
p=0.68).
Patients with AS had decreased serum levels
of CK, aldolase, creatinine, AST and ALT levels
compared with their matched controls (fig 2).
Moreover, patients with AS had a decreased
LBM compared with controls (55.8 (9.4) v
59.2 (9.0) kg; p=0.004). Patients with AS also
had both a lower height (mean (SD) 1.74
(0.10) v 1.77 (0.08) m; p=0.005) and weight
(77 (13) v 83 (13) kg; p=0.03) compared with
controls. When 44 patients with AS using
NSAIDs or second line antirheumatics were
excluded, serum levels of CK (p=0.006) and
ALT (p=0.06), as well as the LBM (p=0.07)
were still largely significantly decreased in
Table 1 Intercorrelation data of biochemical serum markers of skeletal muscle in AS
patients and controls
Aldolase
(IU/l)
Creatinine
(µmol/l) AST (IU/l) ALT (IU/l)
AS patients (n = 58)
CK (IU/l) 0.30 (0.03) 0.04 (0.74) 0.28 (0.03) −0.17 (0.19)
Aldolase (IU/l) 0.14 (0.30) 0.32 (0.02) 0.26 (0.047)
Creatinine (µmol/l) −0.06 (0.66) 0.23 (0.08)
AST (IU/l) 0.32 (0.02)
Controls (n = 60)
CK (IU/l) 0.24 (0.09) 0.18 (0.19) 0.32 (0.02) 0.15 (0.28)
Aldolase (IU/l) −0.26 (0.06) 0.38 (0.005) 0.48 (<0.001)
Creatinine (µmol/l) −0.06 (0.69) −0.03 (0.83)
AST (IU/l) 0.60 (<0.001)
Values are the partial correlation coeYcients (p value), adjusted for age and sex.
Table 2 Intercorrelation data of biochemical serum markers of skeletal muscle and possible determinants in AS patients
and controls
Age (y) BMI (kg/m2)
Lean body mass
(kg) CRP (mg/l)
Disease duration
(y)
AS patients (n = 58)
CK (IU/l) −0.09 (0.49) −0.05 (0.70) −0.02 (0.89) −0.48 (<0.001) 0.03 (0.82)
Aldolase (IU/l) 0.10 (0.47) 0.15 (0.26) 0.14 (0.31) −0.37 (0.005) 0.15 (0.26)
Creatinine (µmol/l) 0.45 (<0.001) 0.26 (0.06) 0.43 (0.001) −0.08 (0.56) −0.22 (0.10)
AST (IU/l) −0.05 (0.72) −0.11 (0.43) −0.06 (0.65) 0.02 (0.86) 0.01 (0.96)
ALT (IU/l) −0.20 (0.14) 0.17 (0.19) 0.34 (0.01) 0.02 (0.84) −0.10 (0.45)
Disease duration (y) 0.63 (<0.001) −0.17 (0.21) −0.14 (0.32) −0.23 (0.09) —
Controls (n = 60)
CK (IU/l) −0.36 (0.006) 0.29 (0.03) 0.15 (0.26) −0.08 (0.56) —
Aldolase (IU/l) 0.02 (0.88) 0.27 (0.05) 0.25 (0.07) 0.07 (0.62) —
Creatinine (µmol/l) 0.23 (0.08) −0.07 (0.60) −0.21 (0.12) 0.00 (0.98) —
AST (IU/l) −0.28 (0.04) 0.32 (0.02) 0.32 (0.02) 0.04 (0.76) —
ALT (IU/l) −0.10 (0.48) 0.40 (0.003) 0.33 (0.01) 0.09 (0.52) —
Values are the partial correlation coeYcients (p value), adjusted for age and sex, or adjusted for sex only when correlated with age.
The lean body mass is estimated by the formula of Deurenberg et al.19
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patients as compared with their matched
controls. When 30 patients with AS were com-
pared with the 30 “healthy” matched controls
only, diVerences were similar and remained
largely significant for serum levels of CK
(p<0.001) and ALT (p=0.07). Intercorrelation
data adjusted for sex and age of serum
biochemical markers are shown in table 1;
additional adjustments for LBM, BMI or CRP
(in AS patients only; normal or increased, that
is, > 10 ng/ml) in partial correlations did not
importantly influence any correlation coeY-
cient, neither in AS patients nor in controls
(data not shown). Correlation coeYcients with
possible determinants of skeletal muscle are
given in table 2. In AS patients, but not in con-
trols, strong negative correlations between
CRP levels and either CK and aldolase levels
were found (table 2 and fig 3). In AS patients,
CRP levels were not significantly correlated
with LBM or BMI (r=0.21, p=0.12 and r=
−0.05, p=0.70, respectively). Disease duration
was strongly and positively correlated with age
(table 2). When comparing the tertile with the
shortest disease duration with that of the long-
est disease duration (adjusted for age in a
ANCOVA), no significant diVerences were
found for the serum biochemical markers of
muscle origin, yet lower mean creatinine level
(p=0.04) and LBM (p=0.06) were found in
late stage AS.
Discussion
This study provides evidence for decreased cir-
culating markers of skeletal muscle in patients
with AS, which seems to represent muscle
wasting. In addition, inverse correlations were
found between CRP levels and CK and
aldolase levels in AS patients, which was
reported previously for CK.5 Our results partly
contradict earlier studies, which reported
raised,7–9 or normal5 10 11 CK levels. In the past
this has even led to the speculation on a patho-
genetic role of skeletal muscle in certain mani-
festations of AS.24 The observed discrepancy
may have been caused by the lack of controls8–10
or the inclusion of less appropriate
controls.5 7 11 Muscle biopsy and electromyo-
graphy studies in patients with AS demon-
strated skeletal muscle disease with neuro-
pathic features,10 25 myopathic features,7 9 11 and
non-specific histological changes.7 9 In AS
patients with severe spinal deformities, atrophy
of type I and type II muscle fibres was found
histologically.25 Perhaps some of the muscle
histological and biochemical findings have
been caused by treatment with high dose phe-
nylbutazone or other NSAIDs.26
Several explanations may be proposed for
the decreased serum levels of sarcoplasmic
enzymes and creatinine. Firstly, in a state of
chronic disease, the overall breakdown of cell
proteins, especially in muscle, may have been
increased to provide the essential amino acids
required for protein synthesis and energy
metabolism.1 27 Hence, a decrease in protein
synthesis or an increase in the proteolytic
machinery, or both, may be a cause of lower
circulating proteins of muscle origin. This idea
is consistent with the finding of a negative cor-
relation between sarcoplasmic enzymes and
CRP levels. This strong inverse relation may
have obscured the inverse correlation between
CK levels and age as well as the positive corre-
lations between CK levels and BMI and LBM,
which were found in our controls. Increased
levels of CRP, or a concomitant increase of
inflammatory cytokines, may lead to an in-
creased encoding of ubiquitin and proteas-
omes, which are part of an intracellular proteo-
lytic system that degrades the bulk of muscle
proteins.1 27 Various disease conditions, such as
sepsis, acidosis, infection (for example, AIDS),
cancer and burns, have all been shown to
increase this ubiquitin-proteasome pathway,
and AS may be an additional condition. This
suggests that pharmacological suppression of
inflammation can help to preserve muscle
mass. This idea does not seem to be compatible
with the similar levels of biochemical markers
of skeletal muscle in AS patients using NSAIDs
or second line antirheumatics compared with
those not using these medication. This may be
explained, however, by the higher disease
activity in patients using such medication, as
documented by their higher geometric mean
CRP level.
Secondly, immobilisation is an important
factor leading to muscle atrophy. In patients
with AS, low physical activity may be attribut-
able to stiVness and pain. Thirdly, sex hor-
mones, and especially anabolic steroids, are
important determinants of muscle mass.28 In
the same study subjects we have shown that
there are no significant diVerences in 17â-
estradiol and testosterone levels between AS
patients and controls.13 However, data on
glucocorticoid, growth hormone, or insulin-
like growth factor-1 metabolism are lacking.
Figure 3 Scatter plot showing the association between C
reactive protein level on a logarithmic scale and serum
creatine kinase and aldolase in 58 patients with AS (in 48
men and 10 women). Partial correlation coeYcients, adjusted
for age and sex, and univariate regression lines are given.
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Fourthly, nutrition and food supply may influ-
ence muscle protein synthesis and breakdown.
Total energy of food intake, however, did not
diVer between AS patients and controls.
Earlier studies reported increased alkaline
phosphatase and ã-glutamyltransferase levels,
as well as increased AST and ALT levels in a
proportion of patients with AS.4 29 30 We did,
however, not find any evidence of liver disease.
Creatinine is formed in the skeletal muscle and
is excreted by the kidneys, mainly by glomeru-
lar filtration. Low serum creatinine levels may
result from a decreased muscle mass and
debilitation, but also from severe hepatic
disease,31 inadequate dietary protein, or in-
creased glomerular filtration. In this respect it
is noteworthy that the glomerular filtration rate
using the Cockcroft and Gault estimate16 did
not diVer between AS patients and controls.
Also, the use of NSAIDs in our AS patients was
not associated with impaired glomerular filtra-
tion rate, which is a side eVect of chronic
NSAID use.32 Assuming a comparable
glomerular filtration, the lower serum creati-
nine in AS patients versus controls may have
resulted from a lower muscle mass. A limitation
of our study was the use of non-fasting serum
samples, which may be of concern for aldolase
measurements. Moreover, the estimation of
LBM based on height, weight, age and sex may
have limited value, because height may be
underestimated because of spinal flexion de-
formities in AS and the assumptions on which
the formula are based may not apply to AS
patients. The shorter height of patients com-
pared with controls was, however, paralleled by
a lower weight. There may be several reasons
for the rather poor associations found between
muscle biochemical markers and LBM. Firstly,
we used a crude estimate for LBM, which rep-
resents the fat free compartment and is
composed not only of muscle mass, but also of
bone mass and extracellular water. Secondly,
serum levels of muscle enzymes are a result of
both production and clearance rates, the latter
is thought to be upregulated in states of chronic
inflammation. Thirdly, these markers also
originate from other tissues than skeletal mus-
cle. Muscle tissue, however, is the common
source of the biochemical markers that were
assessed in this study.
In conclusion, circulating levels of several
muscle enzymes and creatinine are reduced in
patients with AS compared with controls.
These data can be added to the clinical,
electromyographical, and histological evidence
for myopathy in AS. Our data suggest that
muscle wasting is a consequence of disease
activity, which may be mediated through an
increased protein degradation in skeletal mus-
cle. This is also in line with the absence of
inflammatory cells in muscle biopsies.9 10 25
Future studies on myopathy with careful meas-
urement of muscle mass are needed, to usefully
extend our biochemical data to the concept of
muscle wasting in AS.
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